{
    "organizations": [],
    "uuid": "1bd32ce1297994c6735a5eaf91f3a1b1755f4036",
    "author": "",
    "url": "https://www.reuters.com/article/brief-palatin-technologies-announces-sub/brief-palatin-technologies-announces-submission-of-bremelanotide-nda-to-fda-idUSASC09TLC",
    "ord_in_thread": 0,
    "title": "BRIEF-Palatin Technologies Announces Submission Of Bremelanotide NDA To FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26, 2018 / 12:16 PM / Updated 5 minutes ago BRIEF-Palatin Technologies Announces Submission Of Bremelanotide NDA To FDA Reuters Staff 1 Min Read March 26 (Reuters) - Palatin Technologies Inc: * PALATIN TECHNOLOGIES ANNOUNCES SUBMISSION OF BREMELANOTIDE NDA TO FDA FOR TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:",
    "published": "2018-03-26T15:15:00.000+03:00",
    "crawled": "2018-03-26T15:26:21.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "technology",
        "announces",
        "submission",
        "bremelanotide",
        "nda",
        "fda",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "palatin",
        "technology",
        "inc",
        "palatin",
        "technology",
        "announces",
        "submission",
        "bremelanotide",
        "nda",
        "fda",
        "treatment",
        "hypoactive",
        "sexual",
        "desire",
        "disorder",
        "hsdd",
        "premenopausal",
        "woman",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}